Search Results - "Mullane, Stephanie Anne"

The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement by Mullane, Stephanie Anne, Painter, Corrie, Dunphy, Michael, Anastasio, Elana, Simoncelli, Tania, Zarrelli, Kristen, Philippakis, Anthony, McKay, Rana R., Choueiri, Toni K., Golub, Todd, Lander, Eric, Wagle, Nikhil, Van Allen, Eliezer Mendel

“…Abstract only 279 Background: While there has been substantial advancement in the genomic understanding of metastatic prostate cancer (MPC), there is still…”
Get full text

Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials by Sonpavde, Guru, Pond, Gregory Russell, Rosenberg, Jonathan E., Choueiri, Toni K., Bellmunt, Joaquim, Regazzi, Ashley Marie, Mullane, Stephanie Anne, Necchi, Andrea, Raggi, Daniele, Lee, Jae-Lyun, Lee, Soon Il, Simpson, Joseph, Derleth, Christina Louise, Shih-Wen, Lin, Bajorin, Dean F.

“…Abstract only e16012 Background: Surrogate endpoints of benefit in mUC phase 2 salvage therapy trials are necessary to identify promising drugs, particularly…”
Get full text

Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma by Miao, Diana, Margolis, Claire, Martini, Dylan, Mullane, Stephanie Anne, Cullen, Dana, Horak, Christine, Wind-Rotolo, Megan, Hellmann, Matthew David, Voss, Martin Henner, Motzer, Robert J., Norton, Craig, Signoretti, Sabina, Snyder Charen, Alexandra, Van Allen, Eliezer Mendel, Choueiri, Toni K.

“…Abstract only 3016 Background: Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) substantially improve patient survival in clear-cell renal…”
Get full text

Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC) by de Velasco, Guillermo, Madison, Russell, Ali, Siraj Mahamed, Signoretti, Sabina, Mullane, Stephanie Anne, Ross, Jeffrey S., Miller, Vincent A., Stephens, Philip J., Schrock, Alexa Betzig, Young, Lauren, Pal, Sumanta K., Choueiri, Toni K.

“…Abstract only 513 Background: Novel biomarkers are required to accurately assess response in renal cancer. Genomic alterations (GAs) in samples from primary…”
Get full text

Cell-free tumor DNA and TERT promoter mutations in bladder cancer by Huang, Franklin W., Rinne, Mikael L., Lundgren, Kevin T., Mullane, Stephanie Anne, Moreno, Irene, Reed, Sarah, Gydush, Greg, Adalsteinsson, Viktor, Novak, Jesse, Hahn, William C., Signoretti, Sabina, Choueiri, Toni K., Garraway, Levi A., Bellmunt, Joaquim

“…Abstract only 353 Background: Currently, there are no FDA-approved blood biomarkers for the prognosis or prediction of outcomes in urothelial carcinoma (UC)…”
Get full text

Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC) by McKay, Rana R., Martini, Dylan, Moreira, Raphael Brandao, Hamieh, Lana, Norton, Craig, Mullane, Stephanie Anne, Walsh, Meghara K., Michaelson, Dror, McDermott, David F., VanAllen, Eliezer, Harshman, Lauren Christine, Choueiri, Toni K.

“…Abstract only 467 Background: Nivolumab, a monoclonal antibody against PD-1, has been shown to improve survival for pts with mRCC. The current standard of care…”
Get full text

Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival by Pond, Gregory Russell, Sonpavde, Guru, Rosenberg, Jonathan E., Choueiri, Toni K., Bellmunt, Joaquim, Regazzi, Ashley Marie, Mullane, Stephanie Anne, Necchi, Andrea, Raggi, Daniele, Lee, Jae-Lyun, Lee, Soonil, Simpson, Joe, Derleth, Christina Louise, Lin, Shih-Wen, Bajorin, Dean F.

“…Abstract only 346 Background: Early surrogate endpoints of benefit in mUC phase 2 salvage therapy trials are necessary to identify promising drugs,…”
Get full text

The Prostate Cancer Project (PC Project): Translational genomics through direct patient engagement by Mullane, Stephanie Anne, Painter, Corrie, Dunphy, Michael, Anastasio, Elana, Simoncelli, Tania, Zarrelli, Kristen, Philippakis, Anthony, McKay, Rana R., Choueiri, Toni K., Golub, Todd, Lander, Eric, Wagle, Nikhil, Van Allen, Eliezer Mendel

“…Abstract only 199 Background: While there has been substantial advancement in the genomic understanding of prostate cancer (PCa), there is still much to be…”
Get full text

Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer by Liu, David, Abbosh, Philip, Keliher, Daniel, Reardon, Brendan, Mouw, Kent William, Taylor-Weiner, Amaro, Mullane, Stephanie Anne, Han, Garam, Teo, MinYuen, Kim, Jaegil, Al-Ahmadie, Hikmat, Iyer, Gopa, Dulaimi, Essel, Chen, David, Hoffman-Censits, Jean H., Carter, Scott L., Bellmunt, Joaquim, Plimack, Elizabeth R., Rosenberg, Jonathan E., Van Allen, Eliezer Mendel

“…Abstract only 4512 Background: Biomarkers of survival and resistance in chemotherapy-resistant muscle-invasive bladder cancer (MIBC) are not…”
Get full text

The long tail of significantly mutated genes in prostate cancer by Armenia, Joshua, Mullane, Stephanie Anne, Gao, JianJiong, Chakravarty, Debyani, Kundra, Ritika, Huang, Franklin W., Han, G. Celine, Robinson, Dan, Garraway, Levi A., Nelson, Peter, Rubin, Mark A., Taplin, Mary-Ellen, Abida, Wassim, Sawyers, Charles L., Chinnaiyan, Arul M., Kantoff, Philip W., De Bono, Johann S., Schultz, Nikolaus, Van Allen, Eliezer Mendel

“…Abstract only 131 Background: The mutational landscapes of primary and metastatic PCa have been robustly analyzed in multiple whole exome sequencing (WES)…”
Get full text